Floatz logo

Ifosfamide

Nodal Marginal Zone B-cell Lymphoma

University of California, DavisPhase 2Active
B
61/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
49/ 100
Competitive Position
81/ 100

Competitive context

37 Active assets in the Nodal Marginal Zone B-cell Lymphoma cohort.

Asset / SponsorPhaseRating
Cyclophosphamide
SWOG Cancer Research Network
Phase 2BB
Fludarabine
UNC Lineberger Comprehensive Cancer Center
Phase 2BB
ETOPOSIDE
University of California, Davis
Phase 2BB
DEXAMETHASONE
Izidore Lossos, MD
Phase 2BB
CYCLOSPORIN A
National Cancer Institute (NCI)
Phase 2BB

View all 50 →

Same molecule, other indications

Ifosfamide is also rated in:

angioimmunoblastic T-cell lymphomaDormant
BBB
Indicative ·
76 / 100
View asset →
primary mediastinal large B-cell lymphomaDormant
BBB
Indicative ·
76 / 100
View asset →
Hodgkins lymphomaDormant
BBB
Indicative ·
73 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →